We describe the diagnostic and management problems related to the association of facioscapulohumeral muscular dystrophy (FSHD) and myasthenia gravis (MG) in two unrelated patients in whom the diagnosis and hence treatment of myasthenia was delayed because progressive muscle weakness was ascribed erroneously to the underlying muscular dystrophy.
The first patient was a 69-year-old man who had been clinically diagnosed with FSHD, confirmed by deletion analysis (33 kb) 2 years prior to admission, who came to our attention because of the sudden onset of dyspnea, dysphagia, dysarthria, ptosis, and severe weakness of all limbs. Electromyography (EMG) revealed findings suggestive of myopathy. Repetitive nerve stimulation produced a decremental response suggestive of myasthenia gravis. Acetylcholine receptor-binding antibodies were present (12 pmol/L). Muscle biopsy of the biceps brachii demonstrated an increased variability of fiber size, fiber splitting, type II fiber predominance, and several necrotic fibers with cellular infiltrates (Fig. 1) . Dystrophin, utrophin, and sarcoglycan antibody staining were normal. The patient was started on dexamethasone (25 mg daily), azathioprine (50 mg daily), and pyridostigmine (270 mg daily) with remarkable improvement.
The second patient was a 60-year-old man who presented for evaluation of fluctuating dysarthria that began 8 months earlier. On a few occasions he had choked while swallowing. For 5-10 years, he had noticed mild fluctuating difficulty in raising his arms over his head, carrying heavy items, and standing up straight. There was no family history of weakness. On examination there was mild dysarthria and facial and limb-girdle muscle weakness (MRC grade 4). Acetylcholine receptor-binding antibodies were present (4.1 pmol/L). Serum creatine kinase showed a 1.5-fold elevation. The FSHD diagnosis was confirmed by deletion analysis (33 kb). EMG showed short-duration motor unit potentials. Repetitive nerve stimulation produced a decremental response. Pyridostigmine produced modest benefit. Following treatment with mycophenolate mofetil (1000 mg twice daily), the dysarthria and dysphagia improved.
Previous authors have observed the concurrence of myasthenia gravis with myotonic dystrophy 5 or limb-girdle muscular dystrophy, 2 and in another family with familial FSHD. 6 In our Case 1, the diagnosis of MG may have been delayed because at least part of the initial symptoms of fatigability and shortness of breath attributed to FSHD were probably due to untreated MG. Although rare (Ͻ1%), respiratory dysfunction alone may be the presenting symptom of MG. 4 Although atypical phenotypes, such as progressive external ophthalmoplegia, have been described in one family with FSHD, 3 the diagnosis of FSHD was questioned when ptosis and severe bulbar dysfunction developed. In Case 2, the diagnosis of MG and FSHD were made at the same time. It is possible, however, that the fluctuation of proximal weakness noticed prior to the onset of additional bulbar symptoms might have been due to untreated MG.
Up to 80% of muscle biopsies from patients with FSHD show some degree of mononuclear inflammatory cell infiltration. 1 It has been suggested that FSHD is an inflammatory myopathy, but biopsies do not contain non-necrotic muscle fibers focally invaded by T-cells, 1 patients do not benefit from prednisone treatment when assessed carefully by computerized muscle testing in controlled trials, 7 and the presence of abundant mononuclear infiltrates does not affect disease progression. 7 Although the usual diagnostic approach is to unify symptoms and findings under a single diagnosis, the association of myasthenia gravis with FSHD in our two patients is intriguing and raises the possibility that immune mechanisms may be operative in FSHD. 
AIR STACKING FOR COUGH ASSISTANCE
I read with interest the review by Perrin et al. 6 and found it comprehensive except for one important omission. The authors failed to note "air stacking" or the importance of maximal lung insufflations prior to attempts at manually assisted coughing. 4 Likewise, they recommended using mechanical insufflationexsufflation (CoughAssist; J. H. Emerson Co., Cambridge, MA) at insufflation pressures of 20 cm H 2 O, essentially the pressure required for normal tidal volumes in normally compliant lungs. However, the principal reason that we are able to manage patients with neuromuscular diseases without needing to resort to tracheotomy (with the sole exception of patients with advanced bulbar ALS) 2,3 is the effective airway secretion elimination afforded by optimal assisted coughing, that is, manual cough assist from the deep lung volumes of maximally insufflated lungs. 4 Undoubtedly, the reticence to expand lungs to the 60 -70 cm H 2 O pressures that we use routinely stems from the fear of barotrauma so common in patients with primarily lung disease and yet clinically nonexistent in our 800 noninvasive ventilation users. Indeed, our patients invariably find insufflation pressures of less than 35 cm H 2 O to be ineffective or minimally effective at best. Although an average tidal volume may be 600 ml, an average effective cough volume is 2300 ml. 5 It is no surprise that studies that employ nocturnal-only nasal ventilation and ignore effective assisted coughing methods result in minimal benefits to patient longevity. 1 Any review article on long-term noninvasive ventilation is incomplete without recommendations for optimally effective assisted coughing.
